Get the Stockscreener App
0.0593
4.03%
0.0022
Adaptimmune Therapeutics Plc Adr stock is traded at $0.0593, with a volume of 23.22M.
It is up +4.03% in the last 24 hours and down -78.52% over the past month.
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
See More
Previous Close:
$0.0571
Open:
$0.0551
24h Volume:
23.22M
Relative Volume:
0.92
Market Cap:
$15.69M
Revenue:
$175.04M
Net Income/Loss:
$-44.52M
P/E Ratio:
-0.3294
EPS:
-0.18
Net Cash Flow:
$-56.05M
1W Performance:
-18.52%
1M Performance:
-78.52%
6M Performance:
-89.38%
1Y Performance:
-95.01%
1-Day Range:
$0.054
$0.063
1-Week Range:
$0.052
$0.0884
52-Week Range:
$0.052
$1.33
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
Name
Adaptimmune Therapeutics Plc Adr
Sector
Industry
Phone
44 1235 430000
Address
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Compare ADAP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.0592 | 18.55M | 175.04M | -44.52M | -56.05M | -0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
398.85 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.56 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.80 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.92 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-30-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Outperform |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-09-22 | Upgrade | Mizuho | Neutral → Buy |
| May-28-21 | Initiated | Barclays | Underweight |
| Apr-22-20 | Initiated | Mizuho | Neutral |
| Aug-02-19 | Downgrade | Guggenheim | Buy → Neutral |
| May-31-19 | Initiated | ROTH Capital | Buy |
| May-30-19 | Resumed | Citigroup | Buy |
| May-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-17-17 | Initiated | Wells Fargo | Market Perform |
| Oct-24-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Sep-30-16 | Initiated | Raymond James | Outperform |
| Feb-25-16 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | BofA/Merrill | Neutral |
| Jun-01-15 | Initiated | Guggenheim | Buy |
| Jun-01-15 | Initiated | Leerink Partners | Outperform |
View All
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Latest News
Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.
Adaptimmune director Behbahani sells shares worth $229,171 - Investing.com
ADAP’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Wall Street Today: Dow, Nasdaq, S&P 500 open higher as investors focus on optimism over potential US Fed rate cut - Mint
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m By Investing.com - Investing.com India
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m - Investing.com
Adaptimmune stock rating downgraded by H.C. Wainwright after asset sale - Investing.com South Africa
Adaptimmune Therapeutics stock plunges after selling cell therapy assets By Investing.com - Investing.com India
Adaptimmune Therapeutics stock plunges after selling cell therapy assets - Investing.com
Adaptimmune sells cell therapy assets to US WorldMeds for $55 million - Investing.com
Mizuho downgrades Adaptimmune stock on solvency concerns - Investing.com
Financial Metrics Unveiled: MARA Holdings Inc (MARA)’s Key Ratios in the Spotlight - DWinneX
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
Adaptimmune Therapeutics earnings beat by $0.09, revenue fell short of estimates - Investing.com UK
Healthy Upside Potential: Merus N.V (MRUS) - Sete News
How should investors view Jianzhi Education Technology Group Co Ltd ADR (JZ)? - uspostnews.com
All Markets & Instruments Available to Trade - Capital.com
Adaptimmune Therapeutics Plc ADR’s (ADAP) Stock Is Harder To Predict Than You Think - Stocksregister
Take off with Adaptimmune Therapeutics Plc ADR (ADAP): Get ready for trading - Sete News
ADAP (Adaptimmune Therapeutics Plc ADR) may reap gains as insiders became active recently - knoxdaily.com
AUTL’s Market Whiplash: -44.26% YTD Decline, -21.08% Plunge in 30 Days - investchronicle.com
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating Drops and Gains - investchronicle.com
ADAP underperforms with a -5.05 decrease in share price - uspostnews.com
Closing Figures: Myriad Genetics, Inc (MYGN)’s Negative Finish at 7.20, Down -4.00 - DWinneX
Stock Performance Spotlight: Adaptimmune Therapeutics Plc ADR (ADAP) Ends the Day at 0.26, Down by -5.05 - DWinneX
Let’s Jump Into The Geron Corp (NASDAQ: GERN) Stock Forecast - Marketing Sentinel
Bausch + Lomb Corp (NYSE:BLCO)’s 12-Month Price Target Is Now Set At 23. - Marketing Sentinel
B. Riley Financial Inc (NASDAQ:RILY) Shares Dropped -2.22% In A Week. Can It Continue Rising? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) Could Really Rise To 4 In 12 Months, According To Analysts. - Marketing Sentinel
Is Live Oak Bancshares Inc (NYSE:LOB) A Better Buy Than Others After A -32.27% Fall In This Year? - Marketing Sentinel
Eventbrite Inc (NYSE:EB) Declines -81.18% In 2025; Are Investors Attracted By Its $2.10 Price? - Marketing Sentinel
The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - uspostnews.com
How should investors view Lazard Inc (LAZ)? - uspostnews.com
Olema Pharmaceuticals Inc (OLMA)’s results reveal risk - uspostnews.com
It would be worthwhile to take a closer look at Quantum Corp (QMCO) - uspostnews.com
Was there any good news for Neuronetics Inc (STIM) stock in the last session? - uspostnews.com
TransCode Therapeutics Inc: Weathering Stock Market Storms with 8.59M Market Cap - investchronicle.com
Charting the Course: Tempest Therapeutics Inc’s TPST Stock Prospects - investchronicle.com
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com
Adaptimmune Therapeutics Amends Loan Agreement By Investing.com - Investing.com India
Adaptimmune Therapeutics Amends Loan Agreement - Investing.com
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com
Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa
Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Behbahani Ali | Director |
Aug 15 '25 |
Sale |
0.01 |
4,828,206 |
53,110 |
14,671,794 |
1.33%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):